Buscar resultados de ensayos clínicos
Mucopolysaccharidosis Type II - 80 Studies Found
Estado | Estudiar |
Enrolling by invitation |
Nombre del estudio: Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094 Condición: Hunter Syndrome Fecha: 2015-04-01 Intervenciones: Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m |
Completed |
Nombre del estudio: Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Condición: Hunter Syndrome Fecha: 2009-07-09 Intervenciones:
|
Recruiting |
Nombre del estudio: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II Condición: Mucopolysaccharidosis II Fecha: 2017-01-13 Intervenciones: Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor |
Active, not recruiting |
Nombre del estudio: Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Condición: Fecha: 2024-05-19 |
Active, not recruiting |
Nombre del estudio: Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment Condición: Hunter Syndrome Fecha: 2011-12-15 Intervenciones: Drug: Idursulfase-IT Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via |
Completed |
Nombre del estudio: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Condición:
|
Completed |
Nombre del estudio: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Condición:
|
Completed |
Nombre del estudio: Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) Condición:
Fecha: 2013-03-12 |
Completed |
Nombre del estudio: Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) Condición: Mucopolysaccharidosis II Fecha: 1999-10-18 Intervenciones: Genetic: lymphocyte gene therapy |
Completed |
Nombre del estudio: Safety and Efficacy of Hunterase Condición: Hunter Syndrome Fecha: 2012-07-16 Intervenciones: Biological: Hunterase once weekly, 0.5mg/kg IV infusion |